Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy, the branded form of semaglutide, follows a stepwise dose escalation protocol that peaks at 2.4 mg per week. Most patients begin at 0.25 mg and progress through five dose increases over four months. Understanding this dosing pathway helps you anticipate your treatment timeline and cost structure.

Standard Wegovy Dosing Schedule and Maximum Dose

Wegovy's FDA-approved weight loss protocol uses a 16-week initiation phase designed to minimize gastrointestinal side effects while building tolerance. Starting at 0.25 mg weekly, the dose increases every two weeks: 0.5 mg in week three, 1 mg in week five, 1.7 mg in week seven, and finally 2.4 mg in week nine. By week 16, patients maintain the 2.4 mg maintenance dose indefinitely unless tolerability issues require downward adjustment.

Clinical trials showed that the 2.4 mg weekly dose produced the most significant weight loss outcomes, with participants losing approximately 15% of baseline body weight over 68 weeks. Doses below 2.4 mg yielded smaller reductions, typically in the 8–12% range. The maximum dose represents the threshold where efficacy plateaus; increasing beyond 2.4 mg does not yield proportionally greater weight reduction.

Why Semaglutide Dosing Escalates Slowly

The gradual dose escalation exists for two critical reasons: safety and tolerability. Rapid dose increases trigger nausea, vomiting, and loss of appetite in many patients, making the medication difficult to continue. By spacing increases across weeks, your gastrointestinal system adapts progressively, reducing dropout rates and improving long-term adherence.

Each dose step also allows your prescriber to observe how your body responds before advancing further. Some patients reach optimal weight loss at 1.7 mg and experience excessive side effects at 2.4 mg—a scenario where staying at a lower dose remains medically appropriate. Individualized titration, not automatic maximum dosing, drives the best clinical outcomes.

Compounded Semaglutide vs. Brand-Name Wegovy Pricing

Brand-name Wegovy typically costs $900–$1,350 per monthly injection, placing it out of reach for many patients despite insurance eligibility. PlexusDx offers compounded semaglutide injection from licensed 503A compounding pharmacies starting at $149 per month—a fraction of Wegovy's cost. The compounded version uses identical active pharmaceutical ingredients and follows the same clinical dosing protocol.

PlexusDx's flat-rate pricing structure eliminates dose-based cost surprises: whether you receive 0.25 mg or 2.4 mg, your monthly cost remains the same across your titration journey and maintenance phase. This pricing transparency lets you focus on your health progress rather than worrying whether advancing to the next dose will spike your expenses. HSA and FSA accounts cover PlexusDx medications, further lowering your out-of-pocket cost.

Genetic Factors That Influence Semaglutide Response

Not every patient responds identically to semaglutide, even when following the standard dose progression. Genetic variations in the GLP-1 receptor and related appetite-regulation pathways determine how effectively your body processes the medication. PlexusDx's Precision Peptide Genetic Test analyzes key variants—including GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313—that predict your peptide response capacity.

Patients carrying certain genetic signatures may achieve meaningful weight loss at 1.7 mg, while others require the full 2.4 mg dose for comparable results. Understanding your genetic peptide profile enables your prescriber to personalize your titration strategy, potentially accelerating your path to an effective maintenance dose. The Precision Peptide test costs $99 as an add-on after your first month of treatment, providing actionable insights that refine your long-term therapy plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I stay on a lower dose of semaglutide if the maximum dose causes side effects?

Yes. Clinical practice supports dose flexibility; many patients achieve sustained weight loss at 1.7 mg or even 1 mg with fewer gastrointestinal side effects. Your prescriber may pause at any dose level where you reach acceptable efficacy and tolerability balance. Downward dose adjustments are medically appropriate if nausea or appetite loss severely impacts your quality of life.

How long does it take to reach the 2.4 mg maintenance dose?

The standard 16-week titration protocol brings most patients to 2.4 mg by week nine, though the full 16-week period allows your body additional time to stabilize. Some patients stay on the intermediate doses (1.7 mg) for extended periods before advancing further. Your prescriber controls the pace based on your individual tolerability and response.

Is compounded semaglutide from PlexusDx as safe as brand-name Wegovy?

PlexusDx compounded semaglutide comes from licensed 503A compounding pharmacies and contains the same active pharmaceutical ingredient as Wegovy. The compounding process is FDA-regulated, and the medication follows identical clinical dosing and monitoring protocols. Both require a prescription and ongoing medical supervision to ensure safety.

What happens if I miss a weekly semaglutide injection?

If you miss an injection by a few days, take the dose as soon as you remember, then resume your normal schedule the following week. Missing multiple doses may reduce efficacy and potentially restart side effects when you resume. Contact your PlexusDx provider for specific guidance if you miss injections.

Can the Precision Peptide Genetic Test predict whether I'll need the maximum 2.4 mg dose?

The Precision Peptide Genetic Test maps 14 pathways and 150+ genetic insights related to peptide metabolism and appetite regulation, including GLP-1R and MC4R variants. While genetics influence response magnitude, clinical response also depends on individual metabolic factors, lifestyle, and adherence. The test provides predictive guidance to help your prescriber optimize your personalized dosing strategy.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves